what is the difference between compounded tirzepatide and zepbound Mounjaro, Zepbound, Tirzepatide: Understanding Differences | Internal Medicine & Primary Care located in Clifton and Maywood, NJ Tirzepatide (Month 1) 2.5mg |

Food and Drug Administration: (May 2022) Approved as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus (November 2023) Approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (December 2024) Expanded indication for moderate-to-severe obstructive sleep apnea in adults with obesity Classified as first-in-class dual GIP/GLP-1 receptor agonist Not approved for type 1 diabetes mellitus or as monotherapy in patients with history of pancreatitis International Regulatory Approvals GLP2 has received regulatory approval in multiple jurisdictions: European Union (September 2022) Type 2 diabetes treatment United Kingdom (November 2023) Expanded to include weight management Canada (November 2022) Type 2 diabetes indication Australia (December 2022) Type 2 diabetes treatment Additional regulatory reviews ongoing in other countries Warnings and Contraindications Important safety considerations include: Boxed Warning for thyroid C-cell tumor risk (based on rodent studies

Thats why it is suggested to keep changing the site of the injection every week

Therefore, weight loss magnitude was associated with both cumulative treatment exposure proxies and baseline demographic and clinical characteristics

Common (affecting up to 1 in 10 people, usually settling after a few weeks) Uncommon or rare (affecting up to 1 in 100 - or 1 in 1000 if rare - people, contact a doctor if severe) Nausea, diarrhoea, constipation, indigestion, tummy pain, reduced appetite, vomiting, injection-site reactions, dizziness, hair loss Gallstones,pancreatitis (severe abdominal or back pain),injection-site pain, serious allergy, changed sense of taste, change in skin sensation